

(c) the nucleotide sequence as set forth in residues 73 to 451 in SEQ ID NO:1;

(d) a nucleotide sequence encoding the polypeptide as set forth in residues 25 to 144 in SEQ ID NO:2;

(e) the nucleotide sequence as set forth in residues 485 to 820 in SEQ ID NO:1;

(f) a nucleotide sequence encoding the polypeptide as set forth in residues 25 to 113 in SEQ ID NO:2;

(g) a nucleotide sequence encoding the polypeptide as set forth in residues 73 to 113 in SEQ ID NO:2;

(h) a nucleotide sequence encoding the polypeptide as set forth in residues 156 to 267 in SEQ ID NO:2;

(i) a nucleotide sequence which hybridizes under moderately or highly stringent conditions to the complement of at least one of (a) to (h), wherein the encoded polypeptide has an activity of the polypeptide as set forth in SEQ ID NO:2;

(j) a nucleotide sequence complementary to at least one of (a)-(h);

(k) a nucleotide sequence that is at least about 70, 75, 80, 85, 90, 95, 96, 97, 98, or 99 percent identical to at least one of (a)-(j), wherein the nucleotide sequence encodes a polypeptide that has an activity of the polypeptide as set forth in SEQ ID NO:2;

(l) a nucleotide sequence encoding an allelic variant or splice variant of the nucleotide sequence according to at least one of (a)-(j), wherein the encoded polypeptide has an activity of the polypeptide as set forth in SEQ ID NO:2;

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

(m) a nucleotide sequence selected from at least one of (k) and (l) encoding a polypeptide of at least about 25 amino acid residues, wherein the polypeptide has an activity of the polypeptide as set forth in SEQ ID NO:2;

(n) a nucleotide sequence selected from at least one of (k), (l), and (m) comprising a fragment of at least about 16 nucleotides; and

(o) a nucleotide sequence complementary to any of (k), (l), or (m), wherein a culture condition suitable for expressing the polypeptide is selected and the polypeptide is isolated from the culture.

10. (Amended) An apo-A-1 fragment T-cell activation inhibitor-like polypeptide fragment produced by a process comprising culturing a prokaryotic cell comprising a vector comprising a nucleic acid molecule consisting essentially of a nucleotide sequence selected from:

- (a) the nucleotide sequence as set forth in residues 73 to 601 in SEQ ID NO:1;
- (b) a nucleotide sequence encoding the polypeptide as set forth in residues 25 to 194 in SEQ ID NO:2;
- (c) the nucleotide sequence as set forth in residues 73 to 451 in SEQ ID NO:1;
- (d) a nucleotide sequence encoding the polypeptide as set forth in residues 25 to 144 in SEQ ID NO:2;
- (e) the nucleotide sequence as set forth in residues 485 to 820 in SEQ ID NO:1;
- (f) a nucleotide sequence encoding the polypeptide as set forth in residues 25 to 113 in SEQ ID NO:2;
- (g) a nucleotide sequence encoding the polypeptide as set forth in residues 73 to 113 in SEQ ID NO:2;

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

(h) a nucleotide sequence encoding the polypeptide as set forth in residues 156 to 267 in SEQ ID NO:2;

(i) a nucleotide sequence which hybridizes under moderately or highly stringent conditions to the complement of at least one of (a) to (h), wherein the encoded polypeptide has an activity of the polypeptide as set forth in SEQ ID NO:2;

(j) a nucleotide sequence complementary to at least one of (a)-(h);

(k) a nucleotide sequence that is at least about 70, 75, 80, 85, 90, 95, 96, 97, 98, or 99 percent identical to at least one of (a)-(j), wherein the nucleotide sequence encodes a polypeptide that has an activity of the polypeptide as set forth in SEQ ID NO:2;

(l) a nucleotide sequence encoding an allelic variant or splice variant of the nucleotide sequence according to at least one of (a)-(j), wherein the encoded polypeptide has an activity of the polypeptide as set forth in SEQ ID NO:2;

(m) a nucleotide sequence selected from at least one of (k) and (l) encoding a polypeptide of at least about 25 amino acid residues, wherein the polypeptide has an activity of the polypeptide as set forth in SEQ ID NO:2;

(n) a nucleotide sequence selected from at least one of (k), (l), and (m) comprising a fragment of at least about 16 nucleotides; and

(o) a nucleotide sequence complementary to any of (k), (l), or (m), wherein a culture condition suitable for expressing the polypeptide is selected and the polypeptide is isolated from the culture.

15. (Amended) An isolated apo-A-1 fragment T-cell activation inhibitor-like polypeptide fragment consisting essentially of an amino acid sequence selected from:

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

14

(a) an amino acid sequence as set forth in residues 25 to 194 of SEQ ID NO:2; (b) an amino acid sequence as set forth in residues 25 to 144 of SEQ ID NO:2; (c) an amino acid sequence as set forth in residues 156 to 267 of SEQ ID NO:2; (d) an amino acid sequence as set forth in residues 25 to 113 of SEQ ID NO:2; (e) an amino acid sequence as set forth in residues 73 to 113 of SEQ ID NO:2; (f) an amino acid sequence for an ortholog of SEQ ID NO:2, wherein the polypeptide has an activity of the polypeptide as set forth in SEQ ID NO:2; (g) an amino acid sequence that is at least about 70, 80, 85, 90, 95, 96, 97, 98, or 99 percent identical to the amino acid sequence of at least one of (a), (b), or (c), wherein the polypeptide has an activity of the polypeptide as set forth in SEQ ID NO:2; (h) a fragment of the amino acid sequence set forth in at least one of (a), (b), (c), (d), or (e) comprising at least about 25 amino acid residues, wherein the polypeptide has an activity of a polypeptide as set forth in SEQ ID NO:2; (i) an amino acid sequence for an allelic variant or splice variant of at least one of (a)-(f) wherein the polypeptide has an activity of a polypeptide as set forth in SEQ ID NO:2.

16. (Amended) An isolated apo-A-1 fragment T-cell activation inhibitor-like polypeptide fragment encoded by a nucleic acid molecule consisting essentially of a nucleotide sequence selected from:

(a) a nucleotide sequence that is at least about 70, 75, 80, 85, 90, 95, 96, 97, 98, or 99 percent identical to at least one nucleotide sequence selected from:

(1) the nucleotide sequence as set forth in residues 73 to 601 in SEQ ID NO:1;

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

A

- (2) a nucleotide sequence encoding the polypeptide as set forth in residues 25 to 194 in SEQ ID NO:2;
- (3) the nucleotide sequence as set forth in residues 73 to 451 in SEQ ID NO:1;
- (4) a nucleotide sequence encoding the polypeptide as set forth in residues 25 to 144 in SEQ ID NO:2;
- (5) the nucleotide sequence as set forth in residues 485 to 820 in SEQ ID NO:1;
- (6) a nucleotide sequence encoding the polypeptide as set forth in residues 25 to 113 in SEQ ID NO:2;
- (7) a nucleotide sequence encoding the polypeptide as set forth in residues 73 to 113 in SEQ ID NO:2;
- (8) a nucleotide sequence encoding the polypeptide as set forth in residues 156 to 267 in SEQ ID NO:2;
- (9) a nucleotide sequence which hybridizes under moderately or highly stringent conditions to the complement of at least one of (1) to (8), wherein the nucleotide sequence encodes a polypeptide that has an activity of the polypeptide as set forth in SEQ ID NO:2;

(b) a nucleotide sequence encoding an allelic variant or splice variant of the nucleotide sequence selected from at least one of:

- (1) the nucleotide sequence as set forth in residues 73 to 601 in SEQ ID NO:1;

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

A4

- (2) a nucleotide sequence encoding the polypeptide as set forth in residues 25 to 194 in SEQ ID NO:2;
- (3) the nucleotide sequence as set forth in residues 73 to 451 in SEQ ID NO:1;
- (4) a nucleotide sequence encoding the polypeptide as set forth in residues 25 to 144 in SEQ ID NO:2;
- (5) the nucleotide sequence as set forth in residues 485 to 820 in SEQ ID NO:1;
- (6) a nucleotide sequence encoding the polypeptide as set forth in residues 25 to 113 in SEQ ID NO:2;
- (7) a nucleotide sequence encoding the polypeptide as set forth in residues 73 to 113 in SEQ ID NO:2;
- (8) a nucleotide sequence encoding the polypeptide as set forth in residues 156 to 267 in SEQ ID NO:2;
- (9) a nucleotide sequence which hybridizes under moderately or highly stringent conditions to the complement of at least one of (1) to (8), wherein the encoded polypeptide has an activity of the polypeptide as set forth in SEQ ID NO:2;

- (c) a nucleotide sequence selected from at least one of (a) and (b) encoding a polypeptide of at least about 25 amino acid residues, wherein the polypeptide has an activity of the polypeptide as set forth in SEQ ID NO:2;
- (d) a nucleotide sequence selected from at least one of (a), (b), and (c) comprising a fragment of at least about 16 nucleotides; and

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com